Home / Markets / News / Strides Pharma commences export of Favipiravir tablets; stock surges 15%

Strides Pharma commences export of Favipiravir tablets; stock surges 15%

The drug has demonstrated positive outcomes, including a reduction in the duration of Covid-19 and improved lung conditions for the patients

Premium

The company has also entered into a preferred arrangement with a leading Indian API manufacturer for the supplies of Favipiravir API

SI Reporter Mumbai

1 min read Last Updated : Apr 29 2020 | 10:29 AM IST

Shares of Strides Pharma Science surged 15 per cent to Rs 432 on the BSE on Wednesday after the company announced that it has developed and commercialized Favipiravir Antiviral tablets. The product has demonstrated positive outcomes in Covid-19 treatment globally. It is a generic version of Avigan of Toyama Chemical, Japan.

Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan. In February 2020, post the outbreak of Novel Coronavirus (Covid-19), Favipiravir was studied in China and several other countries as an experimental treatment of Covid-19. The drug has demonstrated positive outcomes, including a reduction

Topics : Strides Pharma Science Buzzing stocks Markets

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in